Xuebijing injection (XBJ) and sepsis (septicaemia)

Last edited 05/2023 and last reviewed 05/2023

Xuebijing injection (XBJ) and sepsis (septicaemia)

• an herbal-based intravenous preparation, was licensed in 2004 by the National Medical Products Administration (NMPA, China) for the treatment of sepsis and multiple organ dysfunction syndrome
  
  
• Xuebijing injection (XBJ)
  • possesses an array of activities associated with its mechanism of protection in sepsis
  • can exert an antagonistic effect on endotoxin
  • an inhibitory effect on the uncontrolled release of endogenous inflammatory mediators produced by endotoxin-stimulated monocytes/macrophages
  • can improve the coagulation disorders present in disseminated intravascular coagulation
    
    
• in this randomized clinical trial that included 1817 patients with sepsis, the 28-day mortality rate was 18.8% in the XBJ group vs 26.1% in the placebo group, a significant difference (1):
  • among patients with sepsis, treatment with XBJ, compared with the placebo group, resulted in lower 28-day mortality

Reference:

• Liu S, Yao C, Xie J, et al. Effect of an Herbal-Based Injection on 28-Day Mortality in Patients With Sepsis: The EXIT-SEP Randomized Clinical Trial. JAMA Intern Med. Published online May 01, 2023. doi:10.1001/jamainternmed.2023.0780